Abstract: The invention relates to nitric oxide releasing phosphodiesterase type 5 (PDE5) inhibitors of formula or a stereoisomer or a pharmaceutically acceptable salt thereof: useful for the treatment of ocular condition associated with elevated intraocular pressure such as ocular hypertension, glaucoma or retinopathies.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
May 14, 2024
Assignee:
NICOX S.A.
Inventors:
Nicoletta Almirante, Stefania Brambilla, Laura Storoni, Francesco Impagnatiello, Elena Bastia
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
March 5, 2024
Assignee:
NICOX OPHTHALMICS, INC.
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic gent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, Meibomian gland dysfuntion or skin inflammation or a respiratory disease (e.g., asthma).
Type:
Grant
Filed:
February 17, 2021
Date of Patent:
November 14, 2023
Assignee:
Nicox Ophthalmics, Inc.
Inventors:
Thomas Cavanagh, Shikha P. Barman, Tian Hao, Thomas B. Leland, Ritesh V. Thekkedath
Abstract: The present invention relates to a treatment of vaso-occlusive crisis (VOC) associated with Sickle cell disease by administering a therapeutically effective amount of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
May 30, 2023
Assignees:
NICOX SA, FERA PHARMACEUTICALS, LLC
Inventors:
Brigitte Duquesroix-Chakroun, Frank J. Dellafera, Scott Florentino
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
April 4, 2023
Assignee:
Nicox Ophthalmics, Inc.
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
Type:
Grant
Filed:
July 21, 2020
Date of Patent:
August 9, 2022
Assignee:
NICOX OPHTHALMICS, INC.
Inventors:
Jean-Michel Bukowski, Akshay Nadkarni, José L. Boyer, Brigitte Duquesroix-Chakroun, Tomas Navratil
Abstract: This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I).
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
July 13, 2021
Assignees:
Nicox S.A., Bausch & Lomb Incorporated
Inventors:
Jason Lamar Vittitow, Megan Elizabeth Cavet
Abstract: The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.
Type:
Grant
Filed:
March 11, 2020
Date of Patent:
June 1, 2021
Assignee:
NICOX S.A.
Inventors:
Frédéric Pilotaz, Alan L. Weiner, Marina Do, Julien Saldo
Abstract: The present invention relates to a process for preparing the hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester of formula (I). In accordance with the present invention, the compound (I) can be efficiently prepared with high purity by coupling bimatoprost in a boronate protected form with 6-(nitrooxy)hexanoyl chloride and removing the boronate protecting group. The 6-(nitrooxy)hexanoyl chloride intermediate is prepared by ring-opening reaction of 2-caprolactone and subsequent nitration of the 6-hydroxyhexanoic acid potassium salt with a mixture of HNO3 and H2SO4 in dichloromethane.
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
April 27, 2021
Assignee:
NICOX OPHTHALMICS, INC
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
March 23, 2021
Assignee:
NICOX OPHTHALMICS, INC
Inventors:
Thomas Cavanagh, Shikha P. Barman, Tian Hao, Thomas B. Leland, Ritesh V. Thekkedath
Abstract: The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.
Type:
Grant
Filed:
July 10, 2019
Date of Patent:
June 23, 2020
Assignee:
NICOX SA
Inventors:
Frédéric Pilotaz, Alan L. Weiner, Marina Do, Julien Saldo
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
June 6, 2018
Date of Patent:
June 9, 2020
Assignee:
NICOX OPTHALMICS, INC.
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Abstract: The present invention relates to compositions for treating glaucoma and elevated ocular pressure. The compositions comprise a nitric oxide releasing isomannide derivative and a prostaglandin F2? analog.
Type:
Grant
Filed:
November 17, 2015
Date of Patent:
April 7, 2020
Assignee:
NICOX S.A.
Inventors:
Nicoletta Almirante, Laura Storoni, Elena Bastia, Francesco Impagnatiello
Abstract: The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxy derivatives of fluprostenol.
Type:
Grant
Filed:
January 28, 2016
Date of Patent:
May 7, 2019
Assignee:
NICOX S.A.
Inventors:
Nicoletta Almirante, Laura Storoni, Elena Bastia, Stefania Brambilla, Francesco Impagnatiello
Abstract: The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.
Type:
Grant
Filed:
January 20, 2015
Date of Patent:
March 5, 2019
Assignee:
NICOX S.A.
Inventors:
Eva Prieschl-Grassauer, Martina Morokutti-Kurz, Andreas Grassauer, Sabine Nakowitsch, Angelika Bodenteich, Marielle König-Schuster, Christiane Koller, Frederic Pilotaz
Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
January 8, 2019
Assignee:
NICOX OPHTHALMICS, INC.
Inventors:
Thomas Cavanagh, Shikha P. Barman, Tian Hao, Thomas B. Leland, Ritesh V. Thekkedath
Abstract: The present invention relates to nitric oxide donor carnosine derivatives having a great efficacy in reducing elevated intraocular pressure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
October 9, 2018
Assignee:
NICOX SCIENCE IRELAND
Inventors:
Nicoletta Almirante, Laura Storoni, Elena Bastia, Stefania Brambilla, Sergio Romeo
Abstract: The present invention relates to 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid.
Type:
Grant
Filed:
March 22, 2016
Date of Patent:
August 14, 2018
Assignee:
NICOX S.A.
Inventors:
Nicoletta Almirante, Laura Storoni, Elena Bastia, Stefania Brambilla, Francesco Impagnatiello
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
June 12, 2018
Assignee:
NICOX OPHTHALMICS, INC.
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice